The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...